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L19-IL2 and L19TNFa are fusion proteins composed of L19(scFv), specific for the angiogenesis-associated ED-B containing
fibronectin isoform and IL-2 or TNFa. Because of the tumor targeting properties of L19, IL-2 and TNFa concentrate at
therapeutic doses at the tumor vascular level. To evaluate the therapeutic effects of L19-IL2 and L19mTNFa in neuroblastoma
(NB)-bearing mice, A/J mice bearing Neuro2A or NIE115 NB were systemically treated with L19-IL2 and L19mTNFa, alone or in
combination protocols. Seventy percent of Neuro2A- and 30% of NIE115-bearing mice were cured by the combined treatment
with L19-IL2 and L19mTNFa, and further rejected a homologous tumor challenge, indicating specific antitumor immune
memory. The immunological bases of tumor cure and rejection were studied. A highly efficient priming of CD41 T helper cells
and CD81 CTL effectors was generated, paralleled by massive infiltration in the tumor tissue of CD41 and CD81 T cells at day
16 after tumor cell implantation, when, after therapy, tumor volume was drastically reduced and tumor necrosis reached
about 80%. The curative treatment resulted in a long-lasting antitumor immune memory, accompanied by a mixed Th1/Th2
type of response. Concluding, L19-IL2 and L19mTNFa efficiently cooperate in determining a high percentage of NB cure that,
in our experimental models, is strongly associated to the generation of adaptive immunity involving CD41 and CD81 T cells.
Neuroblastoma (NB) is one of the most common solid
tumors of childhood, accounting for 8–10% of all pediatric
cancers and 15% of cancer-related deaths. Therapy of NB has
mainly consisted of chemotherapy followed by surgical resec-
tion of the tumor or radiotherapy.1 Strategies to address min-
imal residual disease have included high-dose chemotherapy
with autologous hematopoietic stem cell rescue or differentia-
tion of the remaining malignant cells with retinoids.2 How-
ever, because success rates with these approaches have been
limited, alternative strategies, including immunotherapy, have
increasingly become the subject of investigation.3 Inﬂamma-
tory cytokines such as interleukin-2 (IL-2) and tumor necro-
sis factor alpha (TNFa) have been explored for the treatment
of cancers4–7: the former has shown antitumor activity and is
currently used for the treatment of NB mainly because of its
ability to activate and enhance the cytolytic activity of NK
and T cells8,9; TNFa10,11 exerts antitumor effects via a prefer-
ential toxicity for the endothelial cells of the tumor-associated
vasculature, resulting in extensive tumor necrosis, and
through an increase of the antitumor immune response.12–16
The systemic administration of cytokines in pharmacological
doses often produces suboptimal levels in the tumor micro-
environment17 and, as in the case of TNFa, can induce unac-
ceptable toxic side effects that conﬁne their use to strictly
controlled loco-regional treatments.18
We previously demonstrated that B-FN, the ﬁbronectin
isoform containing the extra-domain B (ED-B), is a marker
of angiogenesis,19,20 and that endothelial cells invading tumor
tissues migrate along extra cellular matrix (ECM) ﬁbers con-
taining B-FN.21 Subsequent results demonstrating the possi-
bility to selectively target tumor vasculature using a human
recombinant antibody speciﬁc for B-FN, L19(scFv), in both
experimental animal models and cancer patients,21,22 paved
the way for the antibody’s use in vivo for both diagnostic
and therapeutic purposes. Indeed, the selective targeted
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delivery to the ED-B domain of ﬁbronectin using L19(scFv)
dramatically enhances the anticancer properties of cyto-
kines23–25 and circumvents most of the adverse side effects.
We generated the fusion proteins L19-IL223 and
L19mTNFa,24 conjugating L19(scFv) with human IL-2 and
mouse TNFa (mTNFa), respectively. When injected intrave-
nously (i.v.) into tumor-bearing mice these fusion proteins
selectively accumulate around the tumor vasculature23,24
where they can exert their anticancer activities. For the tu-
mor-targeting and preclinical therapeutic performances,22–24
these fusion proteins are presently undergoing testing in
phase I/II clinical trials.26,27
Both fusion proteins showed anticancer therapeutic effects
that are synergistically enhanced by combined treatment in
preclinical studies.24
With the aim to improve the antitumor efﬁcacy of IL-2,
already used for NB, we treated NB-bearing mice with a
combination of L19-IL2 and L19mTNFa. Herein, we report
the results achieved.
Material and Methods
Animal tumor models
Two different NB cell lines, Neuro2A (N2A, kindly provided
by Dr. S. Ferrini, Laboratory of Immunological Therapy, Isti-
tuto Nazionale per la Ricerca sul Cancro, Genova, Italy) and
NIE-115 (European Collection of Animal Cell Cultures,
Sigma-Aldrich, Milan, Italy), all of A/J origin, were subcuta-
neously (s.c.) implanted in the left ﬂank of immunocompe-
tent syngeneic A/J mice at the dose of 0.25  106 cells/
mouse. All mice were 8 to 10 weeks old and were purchased
from Harlan, UK (Oxon, United Kingdom). The tumor vol-
ume was determined using the following formula: (d)2  D
 0.52; where d and D are the short and long dimensions
(cm) of the tumor, respectively, measured with calipers.28
The mice were sacriﬁced when the tumor reached a volume
of 1.5 cm3. Housing, treatment and sacriﬁce of animals were
compliant with national legislative provisions (Italian law no.
116; January 27, 1992) for the protection of animals used for
scientiﬁc purposes.
Tumor therapy
Groups of NB-bearing mice (when the tumors reached a vol-
ume of about 0.1 cm3) were injected, following the schedule
reported in Figure 2, in their tail vein with the fusion pro-
teins L19mTNFa (0.7 pmol/g in combination therapies and
1 pmol/g as a single drug) and/or L19-IL2 (20 lg ¼ 240,000
IL-2 IU/mouse), or with equivalent amounts of recombinant
mTNFa (Peprotech, London UK), and IL-2 (Proleukin, 18 
106 IU/ml; Chiron, Emeryville, CA) in 100 ll of PBS (20
mM sodium phosphate buffer pH 7.6, 150 mM NaCl). The
expression, puriﬁcation and characterization of the fusion
proteins are reported elsewhere.23,24 Control groups received
100 ll of PBS only. The weight of the animals and the tumor
volume were recorded at 24-hr intervals before and after
treatments. Toxicity was evaluated on the basis of weight
loss, as previously reported.24
In vivo cell subset depletion and in vitro cell
subset selection
In vivo cell subset depletions were performed as previously
described29 following the protocol reported in Figure 4a by
intraperitoneal (i.p.) injections of anti-CD4 (GK1.5; ATTC,
Rockville, MD), anti-CD8 (2.43; ATTC) rat mAbs and antia-
sialo-GM1 (anti-NK rabbit serum; Wako Chemicals GmbH,
Dusseldorf, Germany). Control animals received normal rab-
bit serum or an irrelevant rat mAb, as described.29 In vivo
depletion efﬁciency for each cellular subset was always
>90%, as assessed by immunoﬂuorescence and cytoﬂuorimet-
ric analysis (Becton Dickinson, Milan, Italy) on splenocytes
of 2 mice taken from each group by direct staining with
FITC conjugated anti-CD4 YTS 191.1.2 mAb (Immunotools,
GmbH, Germany), PE-conjugated anti-CD8 YTS 169.4 mAb
(Immunotools), or FITC-conjugated DX-5 mab (Caltag-Med-
systems Limited, Buckingham, UK) for NK cells. For in vitro
selection of CD4þ and CD8þ spleen cells, an immunomag-
netic procedure was used: brieﬂy, negative selection was per-
formed with a pool of mAbs speciﬁc for all cells except
CD4þ or CD8þ cells (CD4þ and CD8aþ T cell isolation kits,
respectively; Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many). Purity was >95%, as assessed by immunoﬂuorescence
and FACS analysis.
Immunohistochemical analyses
Cryostat sections (6 lm thick) were air-dried and ﬁxed in
cold acetone for 10 min. Immunostaining was performed
using a previously described procedure19 and the following
primary antibodies: L19 human IgG1 to detect B-FN,28 anti-
CD4 (GK1.5), anti-CD8 (2.43), antigranulocyte Ly-6G (Gr-1;
clone RB6-8C5; ImmunoKontact, Lugano, Switzerland), anti-
macrophage (clone MOMA-1; ImmunoKontact, Lugano,
Switzerland), anti-B (clone RA3-3A1/6.1; ATCC) and anti-
NK (anti-asialo-GM1, Wako Biochemicals, Osaka, Japan).
Quantitative studies of stained sections were performed inde-
pendently by 3 researchers in a blind fashion. Cell counting
was carried out in 8–12 randomly chosen ﬁelds under a Leica
Wetzlar light microscope (Solms, Germany) at 400 magniﬁ-
cation, 0.180 mm2/ﬁeld. The results are expressed as cell
number per high magniﬁcation microscopic ﬁeld (cell no./
HMMF, mean 6 SE). Mann Whitney U-test was used to
evaluate statistically signiﬁcant differences between the
groups. The percentage of tumor necrosis was evaluated inde-
pendently by 3 researchers on 5 not serial cryostat sections
stained with hematoxylin and eosin at 200 magniﬁcation.
Cell adoptive immunity transfer experiments (Winn assay)
N2A or NIE-115 tumor-cured mice were given a s.c. booster
dose in the contralateral ﬂank with cells derived from the
same tumors (0.25  106) and, after 12 days, the total sple-
nocytes were obtained, following the procedure described by
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Balza et al.30 To establish the amount of effector splenocytes
able to protect naı¨ve mice against N2A or NIE-115 tumor,
different effector-tumor cell ratios (E:T), from 10:1 to 1:1,
were calculated. In the adoptive immunity transfer experi-
ments, an E:T ratio of 5:1 was used with N2A and NIE-115
tumors.
ELISPOT assay
Frequencies of IFN-c- or IL-4-producing spleen cells were
determined using an enzyme-linked immunospot (ELISPOT)
assay performed with ex vivo total splenocytes cocultured
with irradiated N2A or NIE115 tumor cells as antigen, as
described by Mortara et al.31 A >2-fold increase in the num-
ber of spots over the control (splenocytes cultured in the ab-
sence of tumor cells) was considered a positive response. In
certain experiments, mAbs speciﬁc for either MHC class I
(34.1.2S clone, 50 lg/ml) or class II (K24.199 and K22.42.2
clones, 50 lg/ml) antigens were added during the coculture
with irradiated tumor cells. Moreover, immune splenocytes
from N2A tumor-cured mice were stimulated in vitro for
5 days with 10 lg/ml of the following peptides (Tib MolBiol,
Berlin, Germany; kindly provided by Dr S. Ferrini, Istituto
per La Ricerca sul Cancro, Genova, Italy)32: SPSYVYHQF
(gp70env-derived AH1 peptide), and GWEPDDNPI (SURV-
2) and analyzed for IFN-c production, in the absence or
presence of anti-MHC class I (34.1.2S clone, 50 lg/ml) or
anti-MHC class II (K24.199 and K22.42.2 clones, 50 lg/ml)
antibody. Data are expressed as number of spot-forming cells
per million spleen cells.
Cell-mediated cytotoxicity assay
The cell-mediated cytotoxicity assay was performed using
splenocytes from naı¨ve, N2A tumor-cured or N2A tumor-
bearing mice. Splenocytes were cocultured with irradiated
N2A cells for 5 days in the presence of 25 IU/ml IL-2 and
then tested in a standard 4-hr 51Chromium-release assay on
N2A or NIE-115 target cells, as reported by Balza et al.,30 in
the absence or presence of anti-MHC class I (34.1.2S clone,
50 lg/ml) or anti-MHC class II (K24.199 and K22.42.2
clones, 50 lg/ml) antibody.
Results
Eradication of established tumors
Two distinct NB cell lines, Neuro2A (N2A) and NIE-115,
were injected s.c into syngeneic A/J mice at the dose of 0.25
 106 cells/mouse. This dose induces a tumor of about 0.1
cm3 in 8 days. These are fast growing tumors that normally
kill animals in about 3 weeks.
Immunohistochemistry of N2A (Fig. 1c) and NIE115 (Fig.
1d) revealed a strong expression of B-FN at the tumor vascu-
lar level, similar to a staining pattern found in patient-
derived NB specimens (Figs. 1a and 1b). The expression of
Figure 1. Immunohistochemical analysis of the expression of B-FN on cryostat sections of two patient-derived NB specimens (a-b), mouse
N2A (c) and NIE-115 (d) NBs. The pattern of B-FN staining, obtained using L19(scFv), is quite similar in all the tumors tested and restricted
to the vascular level. Scale bars, 10 lm.
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B-FN, a tumor-associated marker and a marker of angiogene-
sis,19,20 is considered an important prerequisite for the
L19(scFv)-driven tumor targeting of effector molecules, as in
the case of the fusion proteins used in this study for thera-
peutic purposes.
We tested the effects of L19-IL2 and L19mTNFa, given
alone or in the combination protocol reported in Figure 2, in
groups of 10 mice bearing N2A tumors of 0.1 cm3. The
results, shown in Figure 2a, indicated that the best therapeu-
tic efﬁcacy in N2A-bearing mice was obtained using the com-
bination of L19mTNFa and L19-IL2 (70% of long-lasting tu-
mor eradication up-to 6 months after therapy). On the other
hand, combined treatment with equivalent amounts of un-
conjugated cytokines resulted in tumor eradication in only
20% of animals. Moreover, treatment with either L19-IL2 or
L19mTNFa alone resulted in only 30% of tumor-cured mice.
The combined treatment with L19mTNFa and L19-IL2 also
led to complete and long-lasting tumor eradication in 30% of
NIE-115-bearing mice (Fig. 2b). The combined treatment was
well tolerated by tumor-bearing mice, as they never had
weight loss exceeding 5% during and after the therapy. The
mice remained tumor-free for at least 6 months after therapy.
Importantly, as previously demonstrated in other tumor
models,30,31 cured mice fully rejected the challenge with a
tumorigenic dose of cells 3 months after therapy, demonstrat-
ing that treatment with L19mTNFa and L19-IL2 induced a
protective immune response in the treated animals.
Tumor tissue correlates of immunity
To gain better insight into the immune-mediated mecha-
nisms associated with treatment, we investigated the pheno-
type of tumor-inﬁltrating leukocytes on N2A cryostat sec-
tions at different times (Fig. 3) in mice untreated and treated
following the protocol reported in Figure 2. Tumors were
removed at day 8, 11 and 16 after tumor cell implantation.
Among the tumor-inﬁltrating cells analyzed, NK cells showed
no differences in the treated and untreated mice at any time
points analyzed (Fig. 3, NK). By contrast, CD4þ and CD8þ T
cells, B cells, macrophages (MU), granulocytes (Gr) and den-
dritic cells (DC) were all statistically signiﬁcantly increased in
treated mice compared to untreated controls, especially at
day 16, when tumor volume was drastically reduced after
therapy and tumor necrosis reached nearly 80% (see Fig. 3).
In vivo depletion of CD81 T cells abolishes the therapeutic
efﬁcacy of L19-IL2 and L19mTNFa
To study the relative contribution of distinct lymphocyte sub-
populations in the early processes leading to tumor cure,
groups of 10 A/J mice were deprived of CD4þ T cells, CD8þ
T cells or NK cells by injecting speciﬁc antibodies or antisera
intraperitoneally, according to the scheme reported in Figure
4a, where day 0 corresponds to N2A tumor cell injection. At
day 8, the therapy was initiated following the protocol also
reported in Figure 4a. Removal of NK cells did not affect the
Figure 2. Therapeutic efﬁcacy of L19-IL2 and L19mTNFa on N2A (a) and NIE-115 (b) mouse NB models. The therapeutic protocol reported
was applied to both models. The different treatments are indicated. Ten mice per group were used and the results are expressed as
survival (%) versus time (d). The arrows indicate the tumor challenge.
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efﬁcacy of the treatment, as 70% of NK-deprived animals
were cured, as were the animals treated with control rat anti-
bodies (Fig. 4b) or rabbit serum (data not shown). Removal
of CD8þ T cells soon after tumor injection and before tumor
therapy totally abrogated the therapeutic effects of the combi-
nation of L19-IL2 and L19mTNFa (Fig. 4b), thus demon-
strating that CD8þ T cells are required for tumor eradication.
Interestingly, when the mice were depleted of CD4þ T cells,
the combined treatment with L19-IL2 and L19mTNFa still
produced tumor eradication in 50% of animals (Fig. 4b).
However, the treatment of CD4þ-deprived mice with
L19mTNFa alone (that cures per se about 30% of immuno-
competent mice, see Fig. 2a), resulted in the complete abro-
gation of therapeutic efﬁcacy (0% of tumor rejecting mice,
see Fig. 4b), strongly suggesting that the presence of CD4þ T
cells was also important in mediating the immune rejection
of tumor, but only in the absence of IL-2. A tumor challenge
at day 50 was rejected by all tumor-cured mice, including the
CD4þ-depleted animals. Taken together, these results indicate
that the efﬁcacy of antitumor treatment is strongly dependent
on the presence of a functional adaptive immune system,
particularly of CD8þ cells and, to a lesser extent, but only in
the combined treatment, of CD4þ T lymphocytes.
Involvement of CD41 and CD81 T cells in tumor rejection
To assess whether immunity generated by the therapeutic
approach could be transferred to naı¨ve syngeneic recipients
by speciﬁc cell subpopulations, we investigated total spleno-
cytes, CD4þ and CD8þ T cells obtained from N2A tumor-
cured mice 12 days after tumor challenge. Unselected spleen
cells fully protected naı¨ve mice against a homologous tumor
challenge (Fig. 4c), CD4þ and CD8þ T cells protected 40%
and 60% of naı¨ve mice, respectively, from tumor take, while
co-injection of CD4þ and CD8þ T cells protected 80% of
mice, thus conﬁrming that both CD4þ and CD8þ tumor spe-
ciﬁc primed T cells are the populations that are mainly
involved in the process of tumor rejection after therapy. To
further detail the functional correlates of antitumor immunity
Figure 3. Evaluation of N2A inﬁltrates, volume variations, and necrosis at day 8, 11 and 16 after tumor cell implant in mice treated with
L19-IL2/L19mTNFa (white columns) and in the untreated counterparts (gray columns). The following inﬁltrating cells were evaluated in
immunohistochemistry using the antibodies reported in the M.M. section: CD4þ T cells (CD4þ); CD8þ T cells (CD8þ); NK cells (NK); B cells
(B); macrophages (MU); granulocytes (Gr); dendritic cells (DC). Three mice per group were used. Results are expressed as the cell number
(mean 6 SE) per HMMF. P values of statistically signiﬁcant differences between the groups connected by dotted lines are also reported.
N2A tumor volume variations (cm3) and necrosis (%) were also evaluated (bottom-middle and -right panels) and expressed as mean 6 SD.
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triggered by the combined therapy with L19-IL2/L19mTNFa,
we evaluated the ability of total spleen cells from N2A tu-
mor-cured mice to kill the NB cell lines in vitro in a classical
4-hr 51Cr release assay. Three months after tumor cure, a low
level CTL response, speciﬁc for N2A or for NIE-115 target
cells, was found (Fig. 5a). At this time, a new challenge of
cured mice with a tumorigenic dose of homologous N2A cells
resulted in boosting CTL activity against homologous and
heterologous tumor cells (Fig. 5b). The boosting of CTL
activity was MHC class I restricted, as shown by the inhibi-
tion of lysis in the presence of anti-MHC class I but not
anti-MHC class II mAbs (Fig. 5c). Importantly, this in vitro
activity was associated with fast and complete tumor rejection
in vivo after a tumor rechallenge (not shown). As CTL activ-
ity was MHC-I-restricted but apparently extended to 2 dis-
tinct tumors, we speculated that the 2 NB cell lines might
express common tumor-associated antigens. We thus investi-
gated the CTL activity against survivin, a pan-tumor antigen
involved in T cell responses in several malignancies, includ-
ing human NB.32 When immune spleen cells were stimulated
in vitro with the MHC class I-restricted GWEPDDNPI survi-
vin peptide or SPSYVYHQF gp70env-derived AH1 peptide
and tested in an IFN-c-ELISPOT assay, there was a high fre-
quency of IFN-c producing spleen cells only in response to
the survivin peptide, thus indicating that response against
survivin was at least part of the antitumor CTL activity gen-
erated in our experimental system (Fig. 5d).
We then evaluated whether the frequency of effector sple-
nocytes producing IFN-c or IL-4, cytokines representative of
type 1- and type 2- responses, respectively, was increased. A
mixed Th1/Th2 response was still present 3 months after tu-
mor cure (Figs. 6a and 6b), thereby indicating that the tumor
immunity was associated with the induction of both Th1 and
Th2 types of response. Moreover, a new tumor challenge
strongly increased the frequency of spleen cells displaying a
Th1/Th2-type of response to tumor cells (anamnestic
immune response), 2 weeks after homologous tumor chal-
lenge. Importantly, both IFN-c- and IL-4-secreting spleen
cells responding to tumor challenge were mostly of the CD4þ
phenotype, as their function was blocked by pretreatment
with anti-MHC class II but not anti-MHC class I antibodies
(Figs. 6a and 6b).
Discussion
All human as well as mouse NBs tested by us strongly
express B-FN at the tumor vascular level (Fig. 1), and this
expression is obviously prerequisite for the tumor drug deliv-
ery strategy based on the targeting ability of L19(scFv), a
human recombinant antibody directed speciﬁcally against this
proven marker of angiogenesis.19–21 Using the combination of
L19-IL2 and L19mTNFa, a stable and long-lasting (up to six
months) tumor eradication was achieved in 70% of N2A- and
in 30% of NIE115-bearing animals (Figs. 2a and 2b). This
result further emphasizes the importance of the synergistic
therapeutic efﬁcacy of combined L19-IL2 and L19mTNFa al-
ready observed by our group in other tumor models.24
One of the most relevant ﬁndings of the present investiga-
tion was the demonstration that the efﬁcacy of the combined
L19-IL2/L19mTNFa treatment against NBs was entirely
dependent on the integrity of the cellular arm of the adaptive
immune response. In fact, the functional elimination of
T cells, particularly CD8þ cells, before administration of
Figure 4. Study of the immune cell populations involved in NB
eradication by therapy with L19-IL2/L19mTNFa (primary phase) and
in the antitumor protection of naı¨ve mice (memory phase). Following
the protocol reported in (A), groups of 10 mice were in vivo depleted
with antibodies or antisera directed to CD4þ or CD8þ T cells or to NK
cells, as described in the M.M. section. N2A-bearing mice, either
depleted or undepleted, were treated with the fusion proteins
following the protocol reported in (a). In (b) the survival curves (%)
versus time (d) of the different groups of mice are reported. The
arrows indicate a new tumor challenge with N2A cells. (c) Survival
curves (%) versus time (d) of groups of 10 naı¨ve mice that received,
at day 0, a s.c. injection of N2A tumor cells and total immune
spleen cells (E:T ¼ 5:1) or in vitro negatively selected CD4þ or
CD8þ T cells or a mixture of CD4þ/CD8þ T cells.
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L19-IL2/L19mTNFa completely abrogated treatment
efﬁcacy. Indeed, CD8þ-deprived mice treated with L19-IL2/
L19mTNFa presented the same frequency of tumor take as
that seen in control mice. These observations are especially
important, as CD8þ CTL are believed to be the major antitu-
mor effectors in vivo. Moreover, they underline the biological
signiﬁcance of the present therapeutic approach not only as a
tool to directly kill the tumor cells in vivo, as we have shown
through immunohistochemical analysis (Fig. 3), but also to
facilitate the triggering of immune effectors that by them-
selves are responsible for complete tumor clearance.
Another relevant ﬁnding of the present investigation is
that the combined therapeutic approach generated a protec-
tive antitumor immune response that was long-lasting and
could be transferred to naı¨ve recipients by adoptive cell
transfer of immune T cells. Thus, the combined approach
serves a dual purpose: to initiate the killing of tumor cells
and to promote the effective immunization of and the acqui-
sition of antitumor memory by the tumor-bearing host that
will hopefully bring about tumor cure. In other words, the
combined treatment induces a therapy-mediated vaccination
against the tumor.
These results are reminiscent of those obtained by our
group in other tumor therapy models, chief of which is the
recently described therapy-induced tumor vaccination of
mouse sarcomas and colon carcinomas after treatment with
L19mTNFa and Melphalan.30,31 In this case, too, the efﬁcacy
of therapy was strictly dependent on the integrity of the adapt-
ive T cell immune response. However, with the L19mTNFa/
Melphalan approach, it was possible to demonstrate the crucial
role played by CD4þ Th cells in triggering and maintaining
the immune response responsible for both tumor cure and tu-
mor rejection upon challenge in tumor-cured mice. In essence,
CD4þ Th cells were shown to be absolutely necessary in order
to trigger, to induce the maturation of and to maintain the ac-
tivity of the major antitumor effectors, the CD8þ CTL.31
At ﬁrst glance, our study would seem to downplay the
role of CD4þ Th cells, as the removal of virgin CD4þ T cells
after NB inoculum, but before combined L19-IL2/
L19mTNFa treatment, did not abrogate therapeutic efﬁcacy
as did the elimination of CD8þ T cells (Fig. 4). However, a
complete analysis of the results and a critical evaluation of
the L19-IL2/L19mTNFa approach versus the L19mTNFa/
Melphalan approach underscores the pivotal function of
Figure 5. Speciﬁc lysis (%) of N2A and NIE115 cells by different E:T ratios of splenocytes from naı¨ve (open symbols) and N2A-cured mice
(closed symbols) at 3 months after therapy with L19-IL2/L19mTNFa (a) and (b) after a s.c. tumor challenge. The speciﬁc lysis (black circles)
was totally inhibited by anti-MHC class I antibodies (open squares) and unaffected by anti-MHC class II antibodies (open triangles) (c).
Results are representative of 3 independent 51Chromium release experiments with similar results. (d) ELISPOT analysis of the frequency of
IFN-c producing spleen cells (mean 6 SD), stimulated with two MHC class I-restricted peptides, revealed that survivin peptide, but not
gp70-env AH1 peptide, activates the release of IFN-c by memory cells that, being inhibited by anti-MHC class I antibodies, are CD8þ
T cells.
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CD4þ Th cells also in this investigation. First of all, elimina-
tion of unprimed CD4þ T cells completely abrogated the
therapeutic efﬁcacy of L19mTNFa treatment, which was
nevertheless capable of curing 30% of tumor-injected mice
(Figs 2 and 4). Second, CD4þ T cells from tumor-cured mice
were capable of transferring protection against tumor take to
40% of naı¨ve mice compared to a protection rate of 60%
transferred by CD8þ T cells, and together the 2 were able to
protect up to 80% of naı¨ve animals in adoptive transfer assays
(Fig. 4c). This indicates that antitumor CD4þ T cell priming
indeed occurred in vivo after combined therapy, and that the
presence of the cells is crucial to maintaining antitumor mem-
ory. Thus, it would appear that CD4þ T cells were less impor-
tant only when L19-IL2 was included in the combined ther-
apy. Taken together, the above ﬁndings strongly suggest that
the availability offered by the combined therapy of IL-2, the
major cytokine required for proliferation of CD4þ and CD8þ
T cells and for the functional activation of CD8þ CTL, may
partially substitute the need during priming of having a large
number of CD4þ Th cells to trigger and to induce the matura-
tion of CD8þ CTL effectors. These and other hypotheses are
presently under investigation in our laboratory.
Further phenotypic and functional characterization of the
lymphocyte subpopulations present in mice undergoing com-
bined L19-IL2/L19mTNFa therapy conﬁrmed that CD4þ Th
cells are present and deeply involved in the antitumor
response generated against NBs. Indeed, spleen cells from tu-
mor-cured mice displayed a mixed Th1/Th2 phenotype with
increased frequency of both IFN-c and IL-4 producing cells,
most of which was inhibited by anti-MHC-II but not anti-
MHC-I antibodies. The ﬁnding that the antitumor response
was associated to a mixed phenotype rather than to the gen-
erally believed unique protective Th1 phenotype is not sur-
prising. Although in some tumor systems a polarized Th2
response promotes, and does not inhibit, tumor growth and
spread,33 in other models a mixed Th1/Th2 immune
response correlates with tumor rejection.34 Interestingly, we
recently detected a protective Th1/Th2 type of immune
response in mice receiving L19mTNFa/Melphalan treat-
ment.31 Thus, a mixed, protective, antitumor Th1/Th2
response may be much more frequent than previously
thought. Taken together, the above results should prompt
careful reconsideration of the rather abused notion that,
in vivo, a polarized Th1 response is synonymous with a pro-
tective antitumor immune response, whereas a polarized Th2
response may even favor tumor growth.
Most clinical experience on the immunotherapy of NB
has focused primarily on monoclonal antibodies to the gan-
glioside GD2 (i.e., ch14.18 monoclonal) that selectively bind
NB cells and facilitate antibody dependent cell-mediated cy-
totoxicity (ADCC) by FcRþ effector cells.35 The ‘‘immunocy-
tokines’’ composed by anti-GD2 antibodies and IL-2 activate
a strong innate immune antitumor response involving NK
cells.36–38 Potential NB-associated antigens capable of evoking
CTL responses do exist, and several studies have shown that
cytotoxic T cells (key immune cells for destroying tumor)
recognize, albeit without clinical relevance, antigens expressed
on the NB cell surface.39–41 Our results indicate that targeting
TNFa and IL-2 to NB vessels by L19(scFv) can cure and vac-
cinate (therapeutic vaccination) animals, which thereafter
reject NB challenge thanks to a tumor-speciﬁc T cell-medi-
ated immune response able to complete the eradication of
any NB residues and to establish a speciﬁc and protective
antitumor memory. The maximum tolerated dose in patients,
already established for L19-IL226,27 and to be calculated at
the end of phase I clinical trials for L19-TNFa, will provide
the basis for planning a clinical trial using the combination
of the two fusion proteins.
In conclusion, we believe that the ﬁndings reported here
pave the way for alternative therapeutic strategies of NB
based on the targeted delivery of biological cytotoxic com-
pounds that not only kill most of the tumor cells but also,
more importantly, trigger an effective and long-lasting antitu-
mor adaptive immune response.
Acknowledgements
The authors thankMr. ThomasWiley for manuscript revision.
Figure 6. ELISPOT analysis of the frequency of IFN-c (a) and IL-4 (b)
producing spleen cells from N2A-cured mice at 3 months after
therapy with L19-IL2/L19mTNFa and after a s.c. tumor challenge
(mean 6 SD). The mixed Th1/Th2 type of response was boosted
by tumor challenge and totally inhibited by anti-MHC class II
antibodies, conﬁrming that tumor-speciﬁc CD4þ Th cells were the
most responsive cells using this test.
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